Astrana Health displayed robust revenue growth in Q4 2024, with an 88.4% increase compared to the same period last year. This growth was driven by strategic expansions and innovations within the company. Despite the revenue surge, the company faced challenges with its EPS, reporting a loss that significantly missed analyst expectations. InvestingPro analysis reveals the company's strong five-year revenue CAGR of 22% and moderate debt-to-equity ratio of 0.68, suggesting sustainable growth potential. For deeper insights into Astrana Health's financial metrics and growth trajectory, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers. The company's strategic expansion into new markets, including Nevada and Texas, and its robust membership growth in the care partner segment underscore its efforts to broaden its reach and improve service offerings.